BR112012023285A2 - métodos para gerar células dendríticas carregadas de antígeno e para eliciar uma resposta imune em um mamífero, e, composição preservável - Google Patents
métodos para gerar células dendríticas carregadas de antígeno e para eliciar uma resposta imune em um mamífero, e, composição preservávelInfo
- Publication number
- BR112012023285A2 BR112012023285A2 BR112012023285A BR112012023285A BR112012023285A2 BR 112012023285 A2 BR112012023285 A2 BR 112012023285A2 BR 112012023285 A BR112012023285 A BR 112012023285A BR 112012023285 A BR112012023285 A BR 112012023285A BR 112012023285 A2 BR112012023285 A2 BR 112012023285A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- antigen
- dendritic cells
- cells
- eliciting
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 210000004443 dendritic cell Anatomy 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title abstract 2
- 239000003755 preservative agent Substances 0.000 title abstract 2
- 230000002335 preservative effect Effects 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000002617 apheresis Methods 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000711 cancerogenic effect Effects 0.000 abstract 1
- 231100000315 carcinogenic Toxicity 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
métodos para gerar células dendríticas carregadas de antígeno e para eliciar uma resposta imune em um mamífero, e, composição preservável. a presente invenção fornece composições e métodos para gerar e criopreservar células dendríticas com funcionalidade superior na produção de sinais mais fortes para as células t, resultando em uma vecina antitumor com base em dc mais potente. a presente invenção inclui dcs maduras, carregadas com antígeno ativadas pelos agosnistas do receptor equivalente a toll que induzem respostas imunes clinicamente eficazes , preferivelmente quando usado mais no principio no processo da doença. as dcs da presente invenção produzem níveis desejáveis de citocinas e quimiocinas, têm ainda a capacidade paar induzir a apoptose das células de tumor. as células podem ser criopreservadas e descongeladas para uso mais tarde, reduzindo deste modo a necessidade para processos de aférese e elutriação repetidas durante a produção de vacina. estes métodos também podem ser utilizados para alvejar diretamente moléculas alvo envolvidas nos caminhos da sinalização carcinogênica e células tronco cancerosas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31398410P | 2010-03-15 | 2010-03-15 | |
PCT/US2011/028487 WO2011115970A1 (en) | 2010-03-15 | 2011-03-15 | System and method of preparing and storing activated mature dendritic cells |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012023285A2 true BR112012023285A2 (pt) | 2018-12-11 |
Family
ID=44649553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012023285A BR112012023285A2 (pt) | 2010-03-15 | 2011-03-15 | métodos para gerar células dendríticas carregadas de antígeno e para eliciar uma resposta imune em um mamífero, e, composição preservável |
Country Status (9)
Country | Link |
---|---|
US (1) | US20130183343A1 (pt) |
EP (2) | EP3424522A1 (pt) |
JP (1) | JP2013522309A (pt) |
CN (1) | CN102933228A (pt) |
AU (1) | AU2011227447B2 (pt) |
BR (1) | BR112012023285A2 (pt) |
CA (1) | CA2793458A1 (pt) |
RU (1) | RU2575978C2 (pt) |
WO (1) | WO2011115970A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170126031A (ko) | 2012-11-13 | 2017-11-15 | 난트 홀딩스 아이피, 엘엘씨 | 칼슘 유동 작동제 및 이의 방법 |
WO2014149871A1 (en) | 2013-03-14 | 2014-09-25 | Icahn School Of Medicine At Mount Sinai | Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer |
US9884087B1 (en) | 2013-05-03 | 2018-02-06 | Chan Soon-Shiong Nanthealth Foundation | Compositions and methods of improved wound healing |
EP3169354A4 (en) | 2014-07-17 | 2018-06-13 | Brian J. Czerniecki | Identification of immunogenic mhc class ii peptides for immune-based therapy |
CA2955445A1 (en) * | 2014-07-17 | 2016-01-21 | Brian J. Czerniecki | Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3 |
WO2016011347A1 (en) * | 2014-07-17 | 2016-01-21 | The Trustees Of The University Of Pennsylvania | Multi-dose injection ready dendritic cell vaccines and combination therapy for cancer |
AU2017201074A1 (en) * | 2014-07-17 | 2017-03-16 | The Trustees Of The University Of Pennsylvania | Manufacturing of multi-dose injection ready dendritic cell vaccines, combination therapies for blocking HER2 and HER3, and estrogen receptor positive HER2 breast cancer therapy |
CN107533065A (zh) | 2015-03-13 | 2018-01-02 | 布莱恩·J·赫尔尼奇 | 在癌症和免疫恢复中监测cd4+1型t辅助细胞应答的方法 |
CN107206061A (zh) * | 2015-05-22 | 2017-09-26 | 布莱恩·J·赫尔尼奇 | 多剂量注射用树突状细胞疫苗的制备,用于阻断her2和her3的联合治疗和雌激素受体阳性her2乳腺癌治疗 |
CA2991212A1 (en) | 2015-07-02 | 2017-01-05 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for combination therapy with dengue virus and dendritic cells |
CA2992925A1 (en) * | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Identification of immunogenic mhc class ii peptides for immune-based therapy |
MX2018003757A (es) * | 2015-09-26 | 2018-09-21 | Primevax Immuno Oncology Inc | Composiciones y metodos para producir celulas dendriticas. |
WO2017189705A1 (en) * | 2016-04-26 | 2017-11-02 | Temple University-Of The Commonwealth System Of Higher Education | Dll4-expressing cells and vaccine using the same |
WO2018031811A1 (en) * | 2016-08-10 | 2018-02-15 | Aurelius Biotherapeutics, Llc | Cell therapy compositions and methods of use thereof |
WO2018061006A1 (en) * | 2016-09-29 | 2018-04-05 | Hadasit Medical Research Services And Development Ltd. | Dendritic cell preparations, compositions thereof and methods of using same |
EP4223868A1 (en) * | 2020-09-30 | 2023-08-09 | National Cancer Center | Enhancement of antitumor effect of immune checkpoint inhibitor through administration of intestinal ruminococcaceae bacterium |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
DE10041515A1 (de) * | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
US20020182231A1 (en) * | 2001-03-23 | 2002-12-05 | Moyer Mary Pat | Methods of stem cell manipulation for immunotherapy |
EP1270732A1 (en) * | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
US20050260208A1 (en) * | 2002-04-11 | 2005-11-24 | Altarex Medical Corp. | Binding agents and their use in targeting tumor cells |
AT412145B (de) * | 2002-09-13 | 2004-10-25 | Forsch Krebskranke Kinder | Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen |
PL209998B1 (pl) * | 2003-02-27 | 2011-11-30 | Northwest Biotherapeutics Inc | Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne |
KR20150032915A (ko) * | 2005-04-08 | 2015-03-30 | 아르고스 쎄라퓨틱스 인코포레이티드 | 수지상 세포 조성물 및 방법 |
EP1806395A1 (en) * | 2006-01-06 | 2007-07-11 | Stichting Sanquin Bloedvoorziening | Maturation of dendritic cells |
EP1840206A1 (en) * | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
JP2009542714A (ja) * | 2006-06-30 | 2009-12-03 | ベイラー リサーチ インスティテュート | GM−CSF及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 |
WO2009023333A2 (en) * | 2007-05-17 | 2009-02-19 | Baylor College Of Medicine | Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines |
EP2072617A1 (en) * | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
-
2011
- 2011-03-15 WO PCT/US2011/028487 patent/WO2011115970A1/en active Application Filing
- 2011-03-15 US US13/635,075 patent/US20130183343A1/en not_active Abandoned
- 2011-03-15 RU RU2012143745/10A patent/RU2575978C2/ru active
- 2011-03-15 EP EP18173217.3A patent/EP3424522A1/en not_active Withdrawn
- 2011-03-15 JP JP2013500149A patent/JP2013522309A/ja active Pending
- 2011-03-15 CN CN2011800240461A patent/CN102933228A/zh active Pending
- 2011-03-15 AU AU2011227447A patent/AU2011227447B2/en not_active Ceased
- 2011-03-15 EP EP20110756841 patent/EP2547360A4/en not_active Withdrawn
- 2011-03-15 CA CA2793458A patent/CA2793458A1/en active Pending
- 2011-03-15 BR BR112012023285A patent/BR112012023285A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2547360A4 (en) | 2013-11-20 |
CN102933228A (zh) | 2013-02-13 |
EP3424522A1 (en) | 2019-01-09 |
EP2547360A1 (en) | 2013-01-23 |
AU2011227447B2 (en) | 2016-04-14 |
RU2012143745A (ru) | 2014-04-20 |
AU2011227447A1 (en) | 2012-10-04 |
JP2013522309A (ja) | 2013-06-13 |
WO2011115970A1 (en) | 2011-09-22 |
US20130183343A1 (en) | 2013-07-18 |
CA2793458A1 (en) | 2011-09-22 |
RU2575978C2 (ru) | 2016-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012023285A2 (pt) | métodos para gerar células dendríticas carregadas de antígeno e para eliciar uma resposta imune em um mamífero, e, composição preservável | |
MX2021009245A (es) | Metodos de preparacion de nanoparticulas lipidicas. | |
BR112012009962A2 (pt) | método para a proliferação de células tantígeno específicas. | |
PH12015501493B1 (en) | Anti-pdgfr-beta antibodies and uses thereof | |
MX336839B (es) | Formacion de complejos de acidos nucleicos con componentes cationicos entrelazados por disulfuro para transfeccion e inmunoestimulacion. | |
AR082686A1 (es) | Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos | |
WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
BR112015015031A2 (pt) | processo de glicoconjugação | |
BR112014032074A2 (pt) | construções de tecido conjuntivo tridimensionais engendradas e métodos de fabricar as mesmas | |
BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
BR112015021888A2 (pt) | inibidores de dna-ik | |
BR112016012794A2 (pt) | Combinação terapêutica de um inibidor de pi3k e um inibidor de btk | |
BR112014018524A8 (pt) | Derivados de pirimido [4,5-b]indol, seus usos, composição farmaceutica, e método in vivo ou ex vivo para aumentar as células estaminais e/ou progenitoras | |
CL2008001933A1 (es) | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
CR10874A (es) | Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3 metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro benzonitrilo y metodos para el uso de los mismos | |
ES2572211T3 (es) | Regeneración de músculo esquelético utilizando células madre mesenquimales | |
BR112013031084A2 (pt) | meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas | |
WO2022066898A3 (en) | Methods of producing extracellular vesicles | |
BR112022018101A2 (pt) | Células hepáticas tipo tronco para tratamento e/ou prevenção de distúrbios hepáticos fulminantes | |
UY31587A1 (es) | Derivados de n-heterociclico-imidazo[1,2-a]piridina-2-carboxamidas, su preparacion y su aplicacion en terapéutica. | |
BRPI0921027A8 (pt) | Cepas de vacina de brachyspira hyodysenteriae | |
AR074406A1 (es) | Celulas madre terapeuticas derivadas de monocitos humanos y un metodo para inducir celulas madre terapeuticas derivadas de monocitos humanos | |
SG196837A1 (en) | Soluble icam-1 as biomarker for prediction of therapeutic response | |
UY31589A1 (es) | Derivados 6-heterociclico-imidazo[1,2-a]piridina-2-carboxamidas, su preparacion y su aplicacion en terapéutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |